

Final - October 19, 2017

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium
 Atlanta, Georgia 30329
 October 25-26, 2017

<u>AGENDA ITEM</u>	<u>PURPOSE</u>	<u>PRESIDER/PRESENTER(s)</u>
<u>Wednesday, October 25</u>		
8:00 Welcome & Introductions		Dr. Nancy Bennett (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary; CDC)
8:30 Herpes Zoster Vaccine Introduction Review of GRADE (ZVL, HZ/su) Cost effectiveness analysis Considerations and proposed recommendations Public comment Vote	Information & Discussion	Dr. Edward Belongia (ACIP, WG Chair) Ms. Angela Guo (CDC/NCIRD) Dr. Lisa Prosser (University of Michigan) Dr. Kathleen Dooling (CDC/NCIRD)
10:30 Break		<u>Vote</u> Dr. Kathleen Dooling (CDC/NCIRD)
10:45 Hepatitis Vaccines Introduction HEPLISAV-B Work Group considerations: HEPLISAV-B Hepatitis A outbreaks	Information & Discussion	Dr. Arthur Reingold (ACIP, WG Chair) Dr. Robert Janssen (Dynavax) Dr. Noele Nelson (CDC/NCHHSTP) Dr. Noele Nelson (CDC/NCHHSTP)
12:15 Lunch		
1:15 Influenza Vaccines Introduction Surveillance update Coverage update LAIV Efficacy/Effectiveness 2016-17 and strain selection update Vaccine Safety Datalink Pregnancy Study Work Group considerations: Influenza vaccines	Information & Discussion	Dr. Chip Walter (ACIP, WG Chair) Ms. Lynnette Brammer (CDC/NCIRD) Dr. Carla Black (CDC/NCIRD) Dr. Raburn Mallory (MedImmune) Dr. James Donahue (Marshfield) Dr. Lisa Grohskopf (CDC/NCIRD)
2:30 Break		
2:45 Mumps Introduction Update on mumps epidemiology in the United States GRADE: third dose of MMR vaccine Considerations and proposed recommendations Public comment Vote VFC vote	Information & Discussion	<u>Vote</u> Dr. Kelly Moore (ACIP, WG Chair) Dr. Mona Marin (CDC/NCIRD) Dr. Mariel Marlow (CDC/NCIRD) Dr. Mona Marin (CDC/NCIRD)
4:30 Vaccine Safety: Shoulder Injury After Vaccination Introduction Data from HRSA Vaccine Injury Compensation Claims Data from the Vaccine Adverse Event Reporting System Communication and Education Campaign	Information & Discussion	<u>VFC Vote</u> Dr. Andrew Kroger (CDC/NCIRD) Dr. Narayan Nair (HRSA) Dr. Tom Shimabukuro (CDC/NCEZID) Dr. Andrew Kroger (CDC/NCIRD)
5:00 Human Papillomavirus (HPV) Vaccines Update Introduction Update	Information	Dr. Peter Szilagyi (ACIP, WG Chair) Dr. Lauri Markowitz (CDC/NCIRD)
5:15 Public Comment		
5:30 Adjourn		

Thursday, October 26

8:00	Agency Updates & Unfinished Business CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO	Information	Dr. Nancy Messonnier (CDC/NCIRD); <i>Ex Officio</i> Members
8:30	Adult Immunization Schedule Introduction Proposed changes in the 2018 adult immunization schedule	<u>Vote</u>	Dr. Laura Riley (ACIP, WG Chair) Dr. David Kim (CDC/NCIRD)
9:00	Child/Adolescent Immunization Schedule Introduction Proposed 2018 child and adolescent schedule revisions	<u>Vote</u>	Dr. José Romero (ACIP, WG Chair) Dr. Candice Robinson (CDC/NCIRD)
9:30	Japanese Encephalitis Vaccine Introduction JE among U.S. travelers JE-VC post-marketing adverse event surveillance among U.S. military Adverse events following JE-VC reported to VAERS, 2012-2016 JE Vaccine Work Group summary and plans	Information & Discussion	Dr. Chip Walter (ACIP, WG Chair) Dr. Susan Hills (CDC/NCEZID) Dr. Christian Taucher (Valneva) Dr. Susan Hills (CDC/NCEZID) Dr. Susan Hills (CDC/NCEZID)
10:30	<i>Break</i>		
10:50	Pneumococcal Vaccines Introduction PCV13 impact on nasopharyngeal carriage among children and adults PCV13 impact on invasive pneumococcal disease: update from Active Progress of the research agenda to inform potential policy change for	Information & Discussion	Dr. Arthur Reingold (ACIP, WG Chair) Dr. Fernanda Lessa (CDC/NCIRD), Ms. Stephanie M. Thomas (Emory University School of Medicine) Dr. Almea Matanock (CDC/NCIRD) Dr. Tamara Pilishvili (CDC/NCIRD)
11:50	Anthrax Vaccines Introduction Preparedness/Operational concerns Anthrax vaccine (BioThrax®) new safety and reactionogenicity data Information on immunogenicity and reactogenicity given by Summary	Information & Discussion	Dr. David Stephens (ACIP, WG Chair) Dr. William Bower (CDC/NCEZID) Dr. Kate Hendricks (CDC/NCEZID) Mr. Jarad Schiffer (CDC/NCIRD) Dr. William Bower (CDC/NCEZID)
1:00	Evidence Based Recommendations	Information	Dr. Wendy Carr (CDC/NCIRD)
1:15	Respiratory Syncytial Virus (RSV) Vaccine	Information	Dr. Gayle Langley (CDC/NCIRD)
1:20	Vaccine Supply	Information	Dr. Jeanne Santoli (CDC/NCIRD)
1:25	Public Comment		
1:40	Adjourn		

Acronyms

- CDC** Centers for Disease Control & Prevention
- CMS** Centers for Medicare and Medicaid Services
- DoD** Department of Defense
- DVA** Department of Veterans Affairs
- FDA** Food and Drug Administration
- GRADE** Grading of Recommendations Assessment, Development and Evaluation
- HRSA** Health Resources and Services Administration
- IHS** Indian Health Service
- JE-VC** Vero cell culture-derived Japanese encephalitis vaccine
- NCHHSTP** National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
- NCIRD** National Center for Immunization & Respiratory Diseases [of CDC/OID]
- NCEZID** National Center for Emerging and Zoonotic Diseases [of CDC/OID]
- NVPO** National Vaccine Program Office
- PCV13** 13-valent pneumococcal conjugate vaccine
- VFC** Vaccines for Children
- WG** Work Group